Zacks.com on MSN14h
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
CRISPR Therapeutics AG (CRSP) closed at $41.17 in the latest trading session, marking a -1.84% move from the prior day.
Zurcher Kantonalbank Zurich Cantonalbank Has $874,000 Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Zurcher Kantonalbank Zurich Cantonalbank raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 3.0% in ...
Farther Finance Advisors LLC Acquires 977 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Farther Finance Advisors LLC boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 34.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & ...
Investing17h
Crispr Therapeutics AG (CRSP)
Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week. InvestingPro subscribers ...
Gene therapy loses luster as investors eye quicker returns from weight-loss drugs
Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward sectors like obesity and cancer, as sales for some of the new treatments ...
GEN - Genetic Engineering and Biotechnology News17h
From Tools to Trials: Editing Therapy Companies Pivot to Development
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
Morningstar11h
Vanguard Small Cap Value Index I
It earns an Above Average Process Pillar rating. The CRSP US Small Cap Index excludes the largest 85% and smallest 2% of US stocks by total market cap. CRSP buckets each eligible constituent in ...